Summary
Bristol-Myers Squibb Company (BMY) filed a Current Report on Form 8-K on April 6, 2007, to announce the filing of its Annual Report on Form 10-K for the year ended December 31, 2006, in XBRL (Extensible Business Reporting Language) format. This filing serves as a test to evaluate the XBRL format and related technology. Investors are cautioned that the XBRL data is unaudited and should not be relied upon for investment decisions. The company emphasizes that the official, audited financial statements in the previously filed Form 10-K are the authoritative source of information. This XBRL submission is purely for technological testing purposes and does not alter the legal or financial implications of the original 10-K filing.
Key Highlights
- 1BMY filed an 8-K on April 6, 2007, related to its 2006 Annual Report.
- 2The primary purpose of the 8-K is to provide the company's 2006 Form 10-K data formatted in XBRL.
- 3This XBRL submission is explicitly stated as a test of XBRL format and technology.
- 4Investors are strongly advised that the XBRL financial information is unaudited.
- 5The company directs investors to rely on the officially filed 10-K and not the XBRL data for investment decisions.
- 6The XBRL information is not considered 'filed' for Section 18 liability purposes and will not be incorporated by reference into other filings without specific mention.
- 7The filing includes various XBRL-related documents, such as Instance, Schema, Calculation, Label, and Presentation Linkbase documents.
Frequently Asked Questions
The main purpose of this 8-K filing is to provide Bristol-Myers Squibb's 2006 Annual Report data formatted in XBRL as a test of this new technology. It is not intended to present new financial information but rather to test the XBRL formatting.
No, investors are strongly cautioned against using the XBRL data for investment decisions. The filing explicitly states that the XBRL financial information is unaudited and that investors should rely on the official, previously filed 10-K.
XBRL (Extensible Business Reporting Language) is a global standard for digitizing business reports to make them more easily searchable and analyzable. Bristol-Myers Squibb is testing it to evaluate the format and related technology as part of the SEC's initiatives to promote digital financial reporting.
No, the company explicitly states that this XBRL information is not considered 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other filings unless specifically stated. Therefore, it does not alter the company's official financial reporting or create new liabilities related to this test submission.